Vanguard Capital Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$95M Sell
9,468,196
-635,613
-6% -$5.88M ﹤0.01% 1551
2026
Q2
$84.6M Sell
10,103,809
-203,062
-2% -$1.85M ﹤0.01% 1645
2026
Q1
$92.9M Buy
+10,306,871
New +$163M ﹤0.01% 1510

Other funds holding ADMA

Vanguard Capital Management's ADMA Position: Q3 2026 in Review

Vanguard Capital Management reduced its ADMA Biologics (ADMA) stake by 6.3% in Q3 2026, selling an estimated $5.88M and leaving 9,468,196 shares worth $95M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Vanguard Capital Management first reported a position in ADMA in Q1 2026 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Vanguard Capital Management held 9,468,196 shares of ADMA Biologics worth $95M as of Q3 2026.
  • Vanguard Capital Management sold 635,613 ADMA Biologics shares in Q3 2026, an estimated $5.88M.
  • ADMA Biologics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1551 holding.
  • Vanguard Capital Management first reported a position in ADMA Biologics in Q1 2026 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.